YUHSpace: Dept. of Internal Medicine (내과학교실)

YUHSpace

BROWSE

YUHSpace1. College of Medicine (의과대학)Dept. of Internal Medicine (내과학교실)

Dept. of Internal Medicine (내과학교실)

Researcher List

Keyword Cloud

Journal Categories

Hot Articles

Trastuzumab in combination with chemotherapy versus chemotherapy alone f...

Yung-Jue Bang ; Eric Van Cutsem ; Andrea Feyereislova ; Hyun C Chung ; Lin Sh... LANCET, Vol.376(9742) : 687-697, 2010

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Jean-Charles Soria ; Yuichiro Ohe ; Johan Vansteenkiste ; Thanyanan Reungwetw... NEW ENGLAND JOURNAL OF MEDICINE, Vol.378(2) : 113-125, 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorecta...

Eric Van Cutsem ; Claus-Henning Köhne ; Erika Hitre ; Jerzy Zaluski ; Chung-R... NEW ENGLAND JOURNAL OF MEDICINE, Vol.360(14) : 1408-1417, 2009

PDF Read more

This table browses all dspace content
Issue Date	Title	Journal Title
2022	Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study	CANCERS
2022	Predicting the Bleeding Risk for Patients on Anticoagulant Therapy Prior to Gastric Endoscopic Submucosal Dissection	JOURNAL OF GASTRIC CANCER
2022	Opening opportunities for women in respiratory medicine: Letter from Korea	RESPIROLOGY
2022	Long-term survival after CCRT and HAIC followed by ALPPS for hepatocellular carcinoma with portal vein invasion: a case report	Journal of Liver Cancer(대한간암학회지)
2022	Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia	JOURNAL OF CLINICAL MEDICINE
2022	Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease	GUT AND LIVER
2022	Long-term outcomes of endoscopic resection followed by additional surgery after non-curative resection in undifferentiated-type early gastric cancer: a nationwide multi-center study	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
2022	Clinical significance of hepatosplenic thrombosis in vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination	INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
2022	Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease	DIABETOLOGIA
2022	Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma	EUROPEAN JOURNAL OF CANCER
2022	Association between serum osteoprotegerin level and renal prognosis in nondialysis patients with chronic kidney disease in the Korean Cohort Study for Outcomes in Patients with Chronic Kidney Disease (the KNOW-CKD Study)	KIDNEY RESEARCH AND CLINICAL PRACTICE
2022	Impaired antibacterial response of liver sinusoidal Vγ9 + Vδ2 + T cells in patients with chronic liver disease	GUT
2022	Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial	CLINICAL CANCER RESEARCH
2022	Clinical impact of pneumothorax in patients with Pneumocystis jirovecii pneumonia and respiratory failure in an HIV-negative cohort	BMC PULMONARY MEDICINE
2022	Generation of a human induced pluripotent stem cell line YCMi004-A from a patient with dilated cardiomyopathy carrying a protein-truncating mutation of the Titin gene and its differentiation towards cardiomyocytes	STEM CELL RESEARCH
2022	Asian perspective on NAFLD-associated HCC	JOURNAL OF HEPATOLOGY
2022	Distinct Gut Microbiota in Patients with Asymptomatic Hyperuricemia: A Potential Protector against Gout Development	YONSEI MEDICAL JOURNAL
2022	Effect of Dupilumab in Korean Patients With Uncontrolled Moderate-to-Severe Asthma: A LIBERTY ASTHMA QUEST Sub-analysis	ALLERGY ASTHMA & IMMUNOLOGY RESEARCH
2022	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE
2022	A first-in-human, open-label, dose-escalation study to investigate the safety and tolerability of CHC2014, a tropomyosin receptor kinase (TRK) inhibitor, in adult patients with advanced solid tumors	ANNALS OF ONCOLOGY